Home Newsfeeds Tesla Granted U.S. Patent #11562231: Neural Networks For Embedded Devices

Tesla Granted U.S. Patent #11562231: Neural Networks For Embedded Devices

https://www.scribd.com/document/621583845/Tesla-Patent

byCharles Gross

January 24, 2023

1 minute read

Canaccord Genuity Initiates Coverage On Sigilon Therapeutics with Buy Rating, Announces Price Target of $6

By Benzinga Newsdesk

January 18, 9:25 AM

Canaccord Genuity analyst Whitney Ijem initiates coverage on Sigilon Therapeutics (NASDAQ:SGTX) with a Buy rating and announces Price Target of $6.

SGTX

News

Novartis Earlier Announced The Phase III APPLAUSE-IgAN Study Met Its Pre-specified Interim Analysis Primary Endpoint, Demonstrating Superiority Of Iptacopan Vs Placebo In Proteinuria Reduction

By Charles Gross

October 2, 4:42 AM

Novartis today announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months1. Iptacopan, an investigational factor B inhibitor targeting the

NVS

Credit Suisse Maintains Outperform on Union Pacific, Lowers Price Target to $240

By Benzinga Newsdesk

January 25, 8:43 AM

Credit Suisse analyst Ariel Rosa maintains Union Pacific (NYSE:UNP) with a Outperform and lowers the price target from $243 to $240.

UNP

‘I Like It Very Much’: Jim Cramer Bullish On This Financial Stock Up 75% YTD

By Avi Kapoor

December 7, 9:52 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes SoFi Technologies, Inc.

CLSK

Tesla Granted U.S. Patent #11562231: Neural Networks For Embedded Devices

Related Posts

Canaccord Genuity Initiates Coverage On Sigilon Therapeutics with Buy Rating, Announces Price Target of $6

Novartis Earlier Announced The Phase III APPLAUSE-IgAN Study Met Its Pre-specified Interim Analysis Primary Endpoint, Demonstrating Superiority Of Iptacopan Vs Placebo In Proteinuria Reduction

Credit Suisse Maintains Outperform on Union Pacific, Lowers Price Target to $240

‘I Like It Very Much’: Jim Cramer Bullish On This Financial Stock Up 75% YTD